USPTO Patent Applications - Organic Chemistry (C07D)

Novel OLED Compound With Rigid Fluorene Substituent - US20260114181A1

USPTO published patent application US20260114181A1 on April 23, 2026, covering a novel organic light-emitting compound where a rigid fluorene-based substituent is introduced into 1,10-phenanthroline. The application (No. 19359671) was filed on October 15, 2025, by inventors A Reum Lee, So Jeong Moon, Joo Hee Jang, Jae Duk Yoo, Young Jae Kwon, Da Young Park, and A Reum Hyun. The compound is designed for use in electron transport layers, hole blocking layers, and N-type charge generation layers of OLEDs to achieve low voltage operation, high efficiency, and extended device lifespan.

Organic Compound for Electroluminescent Devices, US20260114179A1

USPTO published patent application US20260114179A1 on April 23, 2026, covering an organic compound for electroluminescent devices with a structure shown in Formula 1. The application, filed April 12, 2024 under application number 19161669, names inventors Xianbin XU and Lei YANG. The CPC classifications include H10K 85/636, C07D 413/12, and C09K 11/02, indicating applications in organic electronics and semiconductor technology.

Universal Display Corp Organic Electroluminescent Compound Patent Application

Universal Display Corporation filed patent application US20260114182A1 on April 23, 2026, covering a compound of Formula I for organic electroluminescent materials and devices. The application claims compounds with a 5-membered or 6-membered aromatic ring, where at least one of X1 to X3 is nitrogen, with substituents including alkyl, cycloalkyl, aryl, heteroaryl groups, and optional partial or full deuteration. Named inventors are Peter Wolohan, Tyler Fleetham, Jason Brooks, Rasha Hamze, and Nicholas J. Thompson. CPC classifications include H10K 85/6572, C07D 403/14, C07D 487/04, C09K 11/06.

MALT-1 Modulators Patent Application, 13 Inventors, April 2026

The USPTO published patent application US20260109698A1 for MALT-1 modulators, covering compounds and compositions for treating diseases affected by MALT-1 modulation. The application names 13 inventors and was filed on December 18, 2025. This is a publication of a patent application — it does not yet constitute a granted patent or create enforceable intellectual property rights.

Azole Derivatives as SHP2 Inhibitors for Disease Treatment

IRBM S.P.A. has published patent application US20260109699A1 for azole derivatives capable of inhibiting SHP2 phosphatase activity, filed on September 29, 2023 under application number 19114167. The invention covers new chemical compounds and pharmaceutical compositions for treating disorders associated with SHP2 deregulation, with inventors including Alessia Petrocchi, Christian Montalbetti, Romano Di Fabio, Alina Ciammaichella, and Ilaria Rossetti. CPC classifications span C07D 471/20 and multiple A61K therapeutic composition categories.

Nitrogen-Containing Heterocyclic Compounds for Muscarinic Receptor Treatment

USPTO published patent application US20260109700A1 on April 23, 2026, filed October 27, 2023 as Application No. 19121822, disclosing nitrogen-containing heterocyclic compounds represented by formula I and their pharmaceutical salts. The inventors—Deheng Chen, Haifei Jia, Huaqiong Shen, and Lele Zhao—claim the compounds function as positive allosteric modulators of muscarinic receptors for treatment of M receptor-mediated diseases.

Butenolide-Thiazolidinone Compounds as Agricultural Fungicide

The USPTO published patent application US20260109693A1 for butenolide compounds containing a thiazolidinone structure, filed on October 27, 2023 (Application No. 19114226). The five named inventors — Mingan Wang, Xili Liu, Yihao Li, Tingting Zhang, and Qian Zhang — disclosed compounds with general formula (I) characterised by a butenolide-thiazolidinone structure. The published application claims the compounds demonstrate fungicidal activity against agricultural pathogens and may protect crops, horticulture, and livestock from pathogen invasion.

Pyrimidine Derivatives Inhibit c-Kit Kinase for Cancer Treatment

Merck Patent GmbH has filed US Patent Application US20260109697A1, published April 23, 2026, covering 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives as inhibitors of c-Kit kinase for cancer treatment. The application, filed October 30, 2025 (Application No. 19373991), names inventors Dieter Dorsch, Andreas Blum, and Hans-Peter Buchstaller. CPC classifications span C07D 471/04, A61K 31/506, and related pharmaceutical compound categories.

Novel Antibiotic Nidaromycin from New Gene Cluster

The USPTO published patent application US20260109688A1 on April 23, 2026, covering a novel antibiotic compound termed nidaromycin and its associated biosynthetic gene cluster (BGC). The application also discloses related genes, nucleic acid molecules, constructs, vectors, and host cells for producing nidaromycin, as well as methods of use. As a patent application, no enforceable rights exist yet; the invention remains subject to examination before any patent grant.

KCNT1 Inhibitors and Methods of Use

The USPTO published patent application US20260109692A1 covering KCNT1 inhibitors for treating neurological diseases and conditions related to excessive neuronal excitability or gain-of-function mutations in the KCNT1 gene. The application, filed on 2025-10-17 under Application No. 19361128, names James Thomas Reuberson, Sarah Jane Frith, and Vijayendar Reddy Yedulla as inventors. CPC classifications indicate the compounds fall within heterocyclic organic chemistry (C07D) with pharmaceutical applications (A61K).

Heterocyclic Compounds for Immune Response, Cancer Treatment

The USPTO has published patent application US20260109694A1, filed September 23, 2025 (Application No. 19337361), by inventors Liansheng Li and Pingda Ren. The application covers heterocyclic compounds and pharmaceutical compositions designed to potentiate immune response and treat cancer and other diseases. The compounds are classified under multiple CPC codes including C07D 417/10 and A61K 31/4439. This publication represents the initial public disclosure of the patent application following USPTO examination. Patent applications are informational documents that do not grant enforceable rights until a patent issues after substantive examination. Pharmaceutical and biotechnology entities developing immunotherapies or cancer treatments should monitor this application for potential IP overlap with their own compounds or therapeutic approaches.

Small Molecule Protein Synthesis Modulators

The USPTO published patent application US20260109696A1 assigned to Interdict Bio, Inc., filed September 19, 2025 (Application No. 19333657), covering small molecule compounds and pharmaceutical compositions useful for modulating protein synthesis. The disclosed compounds and methods are directed to treating diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, and KRAS-G12D targets.

Peroxiredoxin 3 Inhibitors and Methods of Use for Treating Cancer

USPTO published patent application US20260109695A1 disclosing peroxiredoxin 3 (PRX3) inhibitor compounds of Formula (I) and methods of use for treating cancer. The application, filed August 25, 2023, names three inventors: W. Todd Lowther, Terrence L. Smalley Jr., and Kimberly J. Nelson. The CPC classifications span C07D (heterocyclic compounds) with therapeutic applications in cancer treatment (A61P 35/00).

FBXO7 Inhibitor Compounds for Neurodegenerative Disease Treatment - University of Pittsburgh

The University of Pittsburgh has filed patent application US20260109687A1 covering methods for treating neurodegenerative diseases and inflammatory disorders using FBXO7 inhibitor compounds. The application, filed on July 28, 2025, names Rama K. Mallampalli, Beibei Chen, Charleen T. Chu, and Yuan Liu as inventors. The claimed compounds are chemical inhibitors of the E3 ligase subunit FBXO7 that confer neuroprotection and anti-inflammatory activity by stabilizing mitochondria.

COMPOUNDS AND USES THEREOF - Senolytic Compounds for Aging Treatment

The USPTO published patent application US20260097022A1 for senolytic compounds and methods for treating aging-related conditions. The application covers screening of 2,352 compounds for senolytic activity and trained neural networks to predict activity across over 800,000 molecules. Compounds disclosed bind to Bcl-2 proteins and reduce senescent cell burden. Application filed October 2, 2025; published April 9, 2026.

Tetrahydroquinoline Compounds As Antitumor Agents

USPTO published patent application US20260097029A1 for tetrahydroquinoline compounds of Formula (I) and their salts as disruptors of the FANCM/BTR interaction, useful for hampering FANCM localization to telomeres in tumor treatment. The application (No. 19112485) was filed September 22, 2023 by inventors Sandro Cosconati, Stefano Tomassi, Salvatore Di Maro, and Hilda Amelia Pickett. CPC classifications include A61K 31/4709, A61P 35/00, and C07D 215/06.

Shionogi Fused Ring GLP-1 Receptor Agonist Patent Application

The USPTO published patent application US20260097037A1 by Shionogi & Co., Ltd. on April 9, 2026, covering fused ring compounds as GLP-1 receptor agonists for pharmaceutical use. The application was filed on September 21, 2023, under application number 19112403. The compounds are represented by formulas (I) and (II), with various substituents including phenyl groups and heterocyclic rings.

Fluoro Beta-Carboline Compounds, Bone Formation Method

USPTO published patent application US20260097041A1 for fluoro beta-carboline compounds and methods of promoting bone formation. The application (No. 19202018, filed May 8, 2025) covers compounds of Formula I and their use in orthopedic devices, periodontal devices, and treatment of renal disease, diabetes, bone loss, and cancer. Inventors include Debra Ellies, F. Scott Kimball, and Robert N. Young.

Plasmodium Falciparum Blood Stage Inhibitor Compounds for Malaria Treatment

USPTO published patent application US20260097046A1 disclosing compounds that inhibit Plasmodium falciparum asexual blood stage parasites for malaria treatment. The compounds exhibit sub-millimolar potency against intraerythrocytic stages and are soluble for oral administration. Inventors include Alicia N. Wagner, Roger Trombley, and 8 others. Application filed December 12, 2025.

Conjugates for Cancer Treatment - Patent Application US20260097117A1

USPTO published patent application US20260097117A1 for conjugates comprising a binding moiety and an immunomodulatory imide compound, such as substituted isoindoline compounds, useful for treating cancer. The application was filed October 2, 2025, by inventors Nathan Fishkin and Peter U. Park, with a publication date of April 9, 2026.

Metalloenzyme Inhibitor Compounds (Patent Application US20260097034A1)

USPTO published patent application US20260097034A1 for metalloenzyme inhibitor compounds. The application was filed on October 2, 2025 (Application No. 19348647) by inventors Steven Sparks, Christopher M. Yates, Sammy R. Shaver, and William J. Hoekstra. The patent covers compounds having metalloenzyme modulating activity and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes.

UV/HEV Light Filtering Compounds and Their Use

USPTO published patent application US20260098007A1 for compounds and their use in filtering ultraviolet (UV) and high-energy visible (HEV) light, invented by Micah Nelp and Anthony Young. The compounds may be used in compositions, consumer products, and packaging materials. This patent grant establishes intellectual property rights for the inventors.

Substituted Heterocycle Fused Gamma-Carbolines Synthesis

The USPTO published patent application US20260098040A1 for improved synthesis methods of substituted heterocycle fused gamma-carbolines, filed by inventor Peng Li on April 11, 2025. The application was published April 9, 2026. The document discloses synthesis methods, intermediates, and production processes for these heterocyclic compounds. No regulatory action or compliance obligations are imposed by this publication.

Fused Bicyclic Pyrimidones as WRN Inhibitors

The USPTO published patent application US20260098041A1 assigned to Incyte Corporation, covering tricyclic pyrimidinones as inhibitors of WRN (Werner syndrome helicase). The application names nine inventors and describes pharmaceutical compositions useful in treating diseases or disorders such as cancer or infections. The application was filed on February 26, 2025, under application number 19063574.

GLP-1 Agonist Acid Salt Patent Application

The USPTO published patent application US20260098042A1 for a novel acid salt form of a GLP-1 receptor agonist (OAD2) invented by Haiwen HU, Li FANG, Fan HU, Xinjie ZHOU, and Fenfen CHEN. The compound is classified under CPC C07D 491/056 and may be useful in treating type 2 diabetes and metabolic disorders. The application was filed August 19, 2025, and published April 9, 2026.

Polycyclic Compound for Treatment of Abnormal Cell Proliferation Diseases

USPTO published patent application US20260098043A1 disclosing a polycyclic compound (CLM-L-PTM) or its pharmaceutical salt for treating abnormal cell proliferation diseases. The application names five inventors and covers pharmaceutical compositions suitable for preparing drugs targeting cell proliferation disorders.

Tricyclic Heteroaryl Compounds as Inhibitors of TYK2 and/or JAK1

The USPTO published patent application US20260098044A1 for tricyclic heteroaryl compounds that inhibit TYK2 and/or JAK1 activity. The compounds are directed toward treating skin, respiratory, ophthalmic, and rectal diseases, cancer, and neuroinflammation. Inventors include Stacey Shepard, Onur Atasoylu, Song Mei, and Jun Pan, with application number 19348390 filed October 2, 2025.

Crystalline Form Patent, Tetracyclic Carboxamide, Apr 09

Crystalline Form Patent, Tetracyclic Carboxamide, Apr 09

Rifabutin Analogs for Treatment of M. abscessus Bacterial Infections

USPTO published patent application US20260098046A1 for new rifabutin analog compounds and pharmaceutical compositions for treating bacterial infections, with particular focus on non-tuberculous mycobacteria including M. abscessus. The application was filed on September 29, 2023 by a team of nine inventors. This is a published patent application, not a granted patent.

Anti-Giardial Heterocyclic Compounds for Parasitic Infections

USPTO published patent application US20260098047A1 covering heterocyclic compounds of Formula (I) and (II) for treatment and prevention of Giardiasis (parasitic infection). The application names four inventors and includes pharmaceutical composition claims and methods of using the compounds.

Improved Process for Preparing Risdiplam and Its Intermediates

The USPTO published patent application US20260098048A1 for an improved chemical synthesis process for Risdiplam, a pharmaceutical compound used to treat spinal muscular atrophy. The application also discloses novel intermediates involved in the preparation process. This is a routine patent publication that does not create immediate compliance obligations.

KRAS Modulating Compounds

USPTO published patent application US20260098049A1 for KRAS modulating compounds useful as KRAS inhibitors. The application covers compounds, methods of making and using them, and pharmaceutical compositions. Filed August 11, 2025, with 19 inventors listed.

Nonlinear Optical Chromophores with High Steric Hinderance Substituents for Electro-Optic Devices

Lightwave Logic, Inc. published patent application US20260098206A1 covering nonlinear optical (NLO) chromophores with donors having high steric hindrance substituents, compositions/materials comprising such chromophores, and methods of making and using them in electro-optic devices. The application includes methods of drying and poling, and uses in EOMs. Inventors: Ginelle A. Ramann, Barry L. Johnson, Harvey F. Fulo, Will D. Mikkelsen-Yi.

Lightwave Logic NLO Chromophores 3-Aminocyclohex-2-en-1-one Donor Groups

USPTO published patent application US20260099078A1 by Lightwave Logic, Inc. for nonlinear optical chromophores containing 3-aminocyclohex-2-en-1-one based donor groups. The application covers compositions, materials, and resistive layers comprising these NLO chromophores, methods of making and using them including drying and poling processes, and applications in electro-optic devices such as electro-optic modulators.

Light-Emitting Heterocyclic Compound for Electronic Devices

USPTO published patent application US20260101670A1 for a heterocyclic compound (Formula 1) for use in light-emitting devices and electronic apparatus. The compound is incorporated into the interlayer and emission layer between electrodes. Inventors: Hwasook Ryu, Hankyu Pak, Dongjun Kim, Chaeyeong Kim, Sanghyun Han. Filing date: March 24, 2025.

6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09

6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09

Shionogi Monocyclic GLP-1 Receptor Agonist Patent Application

Shionogi & Co., Ltd. filed USPTO Patent Application US20260098031A1 for a monocyclic compound demonstrating GLP-1 receptor agonist activity, along with pharmaceutically acceptable salts. The compound, classified under CPC codes C07D 405/14 and A61K 31/4439, is intended for pharmaceutical use. The application, published April 9, 2026, claims priority to the September 2023 filing date.

Methods and Compounds for Restoring Mutant p53 Function

USPTO published patent application US20260098032A1 disclosing compounds that bind mutant p53 proteins and restore their wild-type DNA-binding and tumor-suppressor activity. The compounds are directed at reducing cancer progression in tumors harboring p53 mutations. The application was filed on 2025-05-15 under CPC classes C07D 405/14 and related organic chemistry subclasses.

Novel Crystalline Form of Enavogliflozin and Preparation Method

The USPTO published patent application US20260098033A1 for a novel crystalline form of enavogliflozin, an SGLT2 inhibitor for diabetes treatment. The new form exhibits improved thermodynamic stability, reduced hygroscopicity, enhanced long-term storage characteristics, and faster drug absorption compared to prior known forms. The application includes the preparation method and covers pharmaceutical compositions containing the crystalline form.

2H-Benzotriazole Derivative for Treating Premature Ejaculation

USPTO published patent application US20260098034A1 for a 2H-benzotriazole derivative compound and pharmaceutical composition for treating premature ejaculation. The novel benzisothiazole compound demonstrated superior anti-premature ejaculation activity compared to dapoxetine in in-vivo testing. Six inventors are listed with a filing date of August 23, 2023.

Salts and Solid Forms of Piperidine-2,6-Dione for Treating Disorders

USPTO published patent application US20260098035A1 on April 9, 2026, covering novel salts and solid forms of (S)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. Inventors Lianfeng HUANG, Daozhong ZOU, and Tsz Chung LAI filed the application on September 19, 2023, claiming pharmaceutical compositions for treating, preventing, and managing various disorders.

Heteroaryl Pyridazine Carboxamides For Cancer Treatment

The USPTO published patent application US20260098036A1 filed by Deutsches Krebsforschungszentrum covering 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds for cancer treatment. The application claims novel chemical compounds, methods of preparation, pharmaceutical compositions, and methods of treating cancer and disorders associated with aberrant AHR signaling.

Multi-Fused Ring Compound for Diabetes, Obesity

USPTO published patent application US20260098037A1 for a multi-fused ring compound targeting diabetes and obesity. The application (filed September 22, 2025 by inventors Baomin Liu, Yan Zhu, Jinfa Hu, and Yu Huang) claims a compound of formula (I), its stereoisomers, and pharmaceutical compositions containing the compound for treating metabolic diseases. This is a routine patent publication providing public notice of the pending application and its claimed scope.

Yuhan Corporation Patent for Glucosylceramide Synthase Inhibitors

USPTO published patent application US20260098038A1 by Yuhan Corporation for novel 2,3-dihydro-1H-indene and 2,3-dihydrobenzofuran derivatives as glucosylceramide synthase (GCS) inhibitors. The compounds are intended for treating lysosomal storage disorders including Gaucher disease and Fabry disease, as well as neurodegenerative conditions such as Parkinson's disease and Tay-Sachs disease.

Jacobio Pharmaceuticals Patent on Solid Forms of Compound I or Salts Thereof

USPTO published Jacobio Pharmaceuticals' patent application (US20260098039A1) for solid forms of Compound I, a potential cancer therapeutic compound, and its salts. The patent covers novel solid forms, preparation methods, pharmaceutical compositions, and therapeutic uses. The application was filed August 16, 2023, and published April 9, 2026.

MITSUI CHEMICALS Carbamate Compound Patent Application

MITSUI CHEMICALS, INC. published a patent application (US20260098022A1) for a carbamate compound with specific molecular structure parameters. The application describes compounds where R1-R4 form monocyclic or polycyclic rings through various substituent linkages. CPC classifications include C07D 295/205, C07C 271/44, and C07C 275/32. Competitors developing similar chemical structures should review claims upon grant.

Rhodium Catalyst Method for Hydrogenation of Furfural to Bio-Fuel

The USPTO published patent application US20260098023A1 by King Fahd University of Petroleum and Minerals, covering a method for hydrogenating furfural to furfuryl ethyl ether bio-fuel using a rhodium nanoparticle catalyst (0.9-1.1 wt.% on alumina). The reaction achieves at least 99% conversion and 99% selectivity under ethanol and hydrogen atmosphere.

PARP1 Inhibitors and Uses Thereof

USPTO published patent application US20260098024A1 disclosing PARP1 inhibitor compounds and pharmaceutical compositions for cancer treatment. The application, filed on January 26, 2023 under application number 18833362, names six inventors including Robert L. Hoffman and Stephen W. Kaldor and covers compounds classified under C07D 401/12 and C07D 471/04.

Dimeric GYS1 Inhibitor Compounds for Metabolic Disorder Treatment

USPTO published patent application US20260098025A1 covering dimeric compounds of formula (I) as inhibitors of glycogen synthase 1 (GYS1), along with methods of preparing the compounds and methods of treating GYS1-mediated diseases, disorders, or conditions. The application names nine inventors including David John Morgans Jr. and Christopher Joseph Sinz, with an original filing date of September 13, 2023.

M4 Receptor Activators Treat Alzheimer's Parkinson's Schizophrenia

The USPTO published patent application US20260098026A1 for M4 receptor activator/modulator compounds of Formula I, filed September 15, 2023. The compounds are intended for treating M4-mediated neurological disorders including Alzheimer's Disease, Parkinson's Disease, schizophrenia, pain, addiction, and sleep disorders. The application covers the compounds, N-oxides, salts, preparation processes, intermediates, and pharmaceutical compositions.